{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:08:56Z","timestamp":1791605336812,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.bone.2006.06.007","type":"journal-article","created":{"date-parts":[[2006,8,2]],"date-time":"2006-08-02T21:43:20Z","timestamp":1154555000000},"page":"1268-1275","source":"Crossref","is-referenced-by-count":47,"title":["Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis"],"prefix":"10.1016","volume":"39","author":[{"given":"J.C.","family":"Gallagher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Misurski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2006.06.007_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11914-005-0018-6","article-title":"Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction","volume":"3","author":"Miller","year":"2005","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2006.06.007_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079905X41390","article-title":"How useful are measures of BMD and bone turnover?","volume":"21","author":"Miller","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bone.2006.06.007_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2006.06.007_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib5","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/sim.984","article-title":"A method to assess the proportion of treatment effect explained by a surrogate endpoint","volume":"20","author":"Li","year":"2001","journal-title":"Stat. Med."},{"key":"10.1016\/j.bone.2006.06.007_bib6","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1359\/jbmr.1999.14.8.1449","article-title":"Individual smallest detectable difference in bone mineral density measurements","volume":"14","author":"Ravaud","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1385\/JCD:6:4:307","article-title":"Nonresponders to osteoporosis therapy","volume":"6","author":"Lewiecki","year":"2003","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2006.06.007_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JCD:4:2:105","article-title":"Importance of precision in bone density measurements","volume":"4","author":"Bonnick","year":"2001","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2006.06.007_bib9","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1359\/jbmr.1999.14.11.1952","article-title":"Monitoring skeletal changes by radiological techniques","volume":"14","author":"Gluer","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib10","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1385\/JCD:5:3S:S29","article-title":"What is the role of serial bone mineral density measurements in patient management?","volume":"5","author":"Lenchik","year":"2002","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2006.06.007_bib11","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2006.06.007_bib12","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2006.06.007_bib13","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2006.06.007_bib14","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/(SICI)1097-0258(19970830)16:16<1889::AID-SIM607>3.0.CO;2-V","article-title":"Comparative calibration without a gold standard","volume":"16","author":"Lu","year":"1997","journal-title":"Stat. Med."},{"key":"10.1016\/j.bone.2006.06.007_bib15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.06.007_bib19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","article-title":"Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability","volume":"13","author":"Hannon","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2006.06.007_bib21","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.288.15.1889","article-title":"Clinical use of bone densitometry: scientific review","volume":"288","author":"Cummings","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2006.06.007_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s001980050008","article-title":"Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women","volume":"11","author":"Patel","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.06.007_bib23","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2003-1703","article-title":"Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy","volume":"90","author":"Dobnig","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2006.06.007_bib24","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.06.007_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl 1","key":"10.1016\/j.bone.2006.06.007_bib26","first-page":"S521","article-title":"Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: The Fracture Intervention Trial","volume":"13","author":"Bauer","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.06.007_bib27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bone.2003.10.004","article-title":"Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk","volume":"34","author":"Reginster","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.06.007_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib30","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.06.007_bib31","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","article-title":"Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women","volume":"13","author":"Cosman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2006.06.007_bib32","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2006.06.007_bib33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206005680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206005680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T13:40:02Z","timestamp":1555767602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328206005680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S8756328206005680"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2006.06.007","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}